Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance
Key Highlights
- ➤Mesa Labs (MLAB) Q2 revenue $62.336M, up 2.6% year over year
- ➤Operating income rose 77.6% to $8.388M; net income increased 75.3%
- ➤Adjusted EBITDA increased 21.1% to $17.317M, or 27.8% of revenue
- ➤Fiscal 2027 guidance: revenue $250M-$255M and adjusted EBITDA $66M-$68M
- ➤Board authorized a new $40M share repurchase program through December 31, 2028
Expert Statements
Siddhartha Kadia, President and CEO of Mesa Laboratories
“Our second quarter showed the progress we are making and the work that remains. SDC is shipping more reliably on most of its product lines, and the Savings Plan we announced in October is under way. Today we are giving full-year guidance for the first time. We have built it conservatively, on a half-year of data under the changes we have made, because a number that our shareholders can count on is worth more than one that flatters a quarter”
Siddhartha Kadia, President and CEO of Mesa Laboratories
“Mesa is a set of durable, regulation-embedded franchises with real and growing earnings power”
Siddhartha Kadia, President and CEO of Mesa Laboratories
“We have begun to fix the execution issues that held us back. My focus now is disciplined execution and consistent, profitable growth — and this guidance reflects that.”
John Sakys, Chief Financial Officer of Mesa Laboratories
“Second quarter revenues of $62,336 represented 2.6% organic (3.1% constant currency organic) growth, continuing positive organic growth in each quarter of FY27 to date. Growth was driven by SDC and CS, partially offset by BPD, which continued to be impacted by export-control processing delays, and CG. Adjusted EBITDA was 27.8% of revenues versus 23.5% in 2Q26. In the second quarter, we repaid $11,406 of debt and reduced our Total Net Leverage Ratio to 1.75”
LAKEWOOD, Colo., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of critical quality control solutions and life sciences tools, today announced results for its second fiscal quarter (“2Q27”) ended September 30, 2026, and issued full-year guidance for the first time (dollars in thousands, except per-share amounts).
2Q27 Financial Summary – (comparisons are versus the same prior year period) * Revenues increased 2.6% to $62,336 * Non-GAAP organic and constant currency organic revenues(1 )growth was 2.6% and 3.1%, respectively * Non-GAAP revenues excluding Clinical Genomics(6) increased 5.2% (5.8% constant currency) to $52,171; for the first six months, 3.2% (3.3% constant currency) to $102,020 * Sterilization and Disinfection Control revenues increased 14.6% to $25,342; over the last twelve months, the division increased 8.5% to $103,897, the highest twelve-month total revenues in the division’s history * Operating income increased 77.6% to $8,388 * Net income increased 75.3% to $4,341 * Non-GAAP Adjusted EBITDA(2) increased 21.1% to $17,317, or 27.8% of revenues * Repaid $11,406 of debt, and reduced Total Net Leverage Ratio(3) to 1.75 * Issued full-year fiscal 2027 guidance for the first time: revenues of $250,000 to $255,000 and adjusted EBITDA of $66,000 to $68,000 We operate a diversified business across four divisions: Sterilization and Disinfection Control (“SDC”), Biopharmaceutical Development (“BPD”), Calibration Solutions (“CS”), and Clinical Genomics (“CG”).
Get started
Create a free account to read the full story.